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Abstract. Different enantiopure terminal epoxides or 
bromohydrins have chemoselectively been synthesised in 
one-pot starting from the corresponding α-bromoketones 
through alcohol dehydrogenase (ADH)-catalysed processes 
adding an organic co-solvent and tuning appropriately the 
medium pH and the temperature. Thus, at neutral pH 
enantiopure bromohydrins were obtained while using basic 
conditions (pH 9.5-10) epoxides were isolated as the main 
product. Furthermore, by simple selection of the 
biocatalyst, chemo- and stereodivergent transformations 
were achieved to obtain, e.g. enantiopure prolinol or 
piperidin-3-ol. 
Keywords: one-pot reaction; alcohol dehydrogenases; 
epoxides; bromohydrins; prolinol; medium engineering 
 
Enantiopure terminal halohydrins and epoxides are 
valuable functionalities in pharmaceutical industry 
and natural products synthesis due to their high 
reactivity allowing the obtaining of a huge variety of 
compounds.
[1]
 In the last three decades, organo- and 
transition metal-based approaches have successfully 
been developed to synthesise these derivatives.
[2]
 
Otherwise, environmental friendly enzymatic 
processes leading to enantioenriched oxiranes and 
halohydrins have been less developed.
[3]
 Among them, 
kinetic resolutions using epoxide hydrolases (EHs)
[4]
 
and halohydrin dehalogenases (Hhes)
[5]
 have been 
employed to catalyse the regio- and enantioselective 
oxirane ring-opening with H2O or other nucleophiles, 
affording the enantioenriched substrate and product 
with a 50% maximum yield. Recently, an elegant 
chemoenzymatic dynamic kinetic resolution 
procedure leading to aromatic terminal epoxides has 
been published.
[6]
 Thus, coupling an Ir catalyst which 
promoted the racemisation of the halohydrins with an 
Hhe, several (R)-oxiranes could be achieved with 
moderate to high conversions and high 
enantioselectivities. Another approach has been the 
P450 monooxygenase-catalysed asymmetric 
epoxidation of terminal olefins.
[7]
 Halohydrins have 
been obtained through stereoselective reduction of α-
haloketones using alcohol dehydrogenases (ADHs).
[8]
 
Likewise, terminal epoxides have also been prepared 
through ADH-based sequential or cascade 
protocols.
[9]
 In those systems, a terminal α-
chloroketone was stereoselectively reduced with an 
ADH to the corresponding enantiopure chlorohydrin 
that subsequently cyclisised through Hhe-
[9a-c]
 or 
base-catalysed
[9d]
 intramolecular SN2 reaction, 
leading to the epoxides with moderate to high 
conversions and excellent ees. Similarly, a “designer-
cell”-based two-step procedure was developed to 
synthesise (S)-octene oxide.
[10]
 It is noteworthy that 
pH around 13 was set in order to accomplish the 
oxirane ring-formation,
[9d,10]
 that can be incompatible 
with other functionalities. 
With this scenario we assumed that employing α-
bromoketones
[10,11]
 instead of α-chloroketones, we 
could synthesise enantioenriched terminal oxiranes or 
bromohydrins in one-pot by simple use of a catalyst 
(an ADH) and a catalytic amount of cofactor 
employing 2-propanol to recycle it („substrate-
coupled‟ approach)[12] at suitable pH conditions for 
the enzyme (Scheme 1). Furthermore, an application 
to obtain N-heterocyclic compounds is also shown. 
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Scheme 1. One-pot synthesis of enantiopure terminal 
epoxides. 
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For this purpose, we chose 1-bromooctan-2-one 
(1a)
[10]
 as model substrate. Using Lactobacillus brevis 
ADH (LBADH)
[13]
 as catalyst at pH 7.5, only 10% of 
enantiopure (S)-epoxide 3a was obtained after 24 h, 
so Tris.SO4 buffers ranging from pH 7.5 until 10 
were tested (see Supporting Information). Obviously, 
the best conversion into 3a (47%) was found with the 
highest pH, although we observed that other minor 
compounds were also formed. In this sense, blank 
experiments demonstrated that the corresponding 
hydroxyketone (4a) was formed by SN2 reaction over 
substrate 1a, and diol 5a appeared due to the ADH-
catalysed reduction of 4a.
[14]
 To circumvent this fact 
it was envisaged that an amount of a water-
immiscible solvent could result in a reservoir for both 
substrate and products (Scheme 2). 
 
Scheme 2. (Bio)transformations in a biphasic aqueous-
organic system. 
Consequently, several organic solvents such as n-
pentane, n-hexane, cyclohexane, n-heptane and n-
decane were assayed at 5% v v
-1
 leading to almost 
exclusive formation of 2a and 3a after 24 h, although 
the cyclisation rate diminished (see Supporting 
Information). Since no relevant difference was 
noticed among them, n-hexane was selected as the 
organic co-solvent. The addition of the organic phase 
was advantageous to suppress the undesired SN2 
reaction over α-bromoketone 1a, but also delayed the 
enzymatic reduction to obtain 2a and the ring-closure 
to achieve 3a, so a compromise had to be found. To 
optimise the reaction outcome, a study of the n-
hexane concentration (3-20% v v
-1
) was carried out 
(Figure 1). As expected, it was observed that at 
higher percentages of the organic co-solvent, less 
quantity of by-products was formed although going in 
hand with a lower cyclisation rate. Hence, 5% v v
-1
 of 
n-hexane was the compromise concentration. 
 
Figure 1. Co-solvent concentration effect on the products 
ratio in the biotransformation of 1a into 3a after 24 h. 
In these conditions, we observed a clean reaction 
with complete consumption of 1a and a promising 
42% of 3a after 24 h. In an attempt to maximise the 
oxirane formation, it was designed a thermally 
controlled experiment consisting of the enzymatic 
bioreduction at 30ºC followed by the intramolecular 
SN2 transformation at 45ºC by simply setting a 
temperature program. Thus, the reaction progress at 
30ºC was studied (Figure 2) to check the time needed 
to consume α-bromoketone 1a. As can be noted after 
12 h this compound disappeared, only forming traces 
(<2%) of diol 5a. 
 
Figure 2. Time-course of the enzymatic transformation of 
1a into 3a catalysed by LBADH in Tris.SO4 buffer pH 10 
at 30ºC in the presence of 5% v v
-1
 of n-hexane. 
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Table 1. Biocatalysed synthesis of enantiopure epoxides and bromohydrins in a biphasic system.
[a]
 
entry 1 conv.
[b]
 ee
[c,d]
 2
[b]
 3
[b]
 T program pH ADH 
1 1a 98 >99 (S) 56 42 24h 30ºC 10 LB 
2 1a 99 >99 (S) <1 98 13h 30ºC /18h 45ºC 10 LB 
3 1a >99 >99 (R) 9 90 13h 30ºC /18h 45ºC 10 T 
4
[e]
 1b >99 >99 (S) <1 84 13h 30ºC /18h 45ºC 9.5 LB 
5 1b 99 >99 (R) <1 98 13h 30ºC /18h 45ºC 9.5 T 
6 1c 87 >99 (S) 4 83 36h 30ºC 9.5 LB 
7 1a >99 >99 (S) 99 <1 18h 30ºC 7.5 LB 
8 1a 99 >99 (R) 98 <1 18h 30ºC 7.5 T 
9 1b >99 >99 (S) 85 15 18h 30ºC 7 LB 
10 1b >99 >99 (R) 93 7 18h 30ºC 7 T 
11 1c >99 >99 (S) 99 <1 18h 30ºC 7.5 LB 
[a] For reaction conditions, see Supporting Information. [b] Measured by GC. [c] Measured by chiral GC or HPLC. [d] 
Switch in Cahn-Ingold-Prelog (CIP) priority. [e] 15% of by-products were formed. 
Thus, employing a program that comprised 13 h at 
30ºC followed by 18 h at 45ºC excellent epoxide 
conversion was achieved (Table 1). This one-pot 
sequential process enabled the formation of 
enantiopure (S)- or (R)-3a with excellent yields by 
simple selection of the biocatalyst, using either 
LBADH (entry 2) or ADH from Thermoanaerobacter 
sp.
[15]
 (ADH-T, entry 3), respectively. 
Since this one-pot two-step procedure rendered 
excellent results for this aliphatic substrate, we 
decided to apply this methodology with an aromatic 
ketone such as α-bromo-p-nitroacetophenone (1b), 
obtaining with ADH-T a complete conversion of 
enantiopure (R)-p-nitrostyrene oxide (3b), and a 
conversion of 84% and >99% ee of (S)-3b using 
LBADH (Table 1, entries 4-5). For this derivative a 
slightly lower pH (9.5) was chosen, since at pH 10 
higher amounts of by-products were detected. 
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Scheme 3. Chemo- and stereodivergent preparation of β-
bromo alcohols and epoxides starting from α-
bromoketones. Conditions A: ADH, 2-propanol, Tris.SO4 
buffer pH 9.5-10, n-hexane, 30ºC plus a 45ºC period. 
Conditions B: ADH, 2-propanol, Tris.SO4 buffer pH 7-7.5, 
n-hexane, 30ºC. 
Furthermore, taking benefit from the versatility of 
the medium parameters, we can use this methodology 
to synthesise selectively the corresponding 
bromohydrins with high conversions and optical 
purities. Since it was observed in previous 
experiments that lower pHs and the presence of an 
organic co-solvent diminished the cyclisation rate, we 
exploited this to obtain the bromohydrins 2a-b 
(Scheme 3). Therefore, experiments were carried out 
at lower pH (7-7.5) and 30ºC with 5% v v
-1
 n-hexane 
(entries 7-10). Thus, enantiopure derivatives (S)- and 
(R)-2a-b were preferentially obtained using both 
ADHs. To show the feasibility of these protocols, 
enantiopure (S)-alcohol 2a and (S)-epoxide 3a were 
prepared on a higher scale starting from 120 mg of 
the α-bromoketone 1a with excellent isolated yields 
(see SI). 
At this point we were interested in applying this 
methodology to obtain other valuable derivatives. 
Enantiopure prolinol and related structures are 
important chiral auxiliaries in hydrogen transfer 
protocols as well as asymmetric epoxidations and 
catalysts in aldol condensations, Michael type 
additions and other C-C bond-forming reactions.
[16]
 
Moreover, chiral N-containing heterocycles are quite 
common in natural alkaloids and derivatives,
[17]
 and 
therefore, it becomes interesting to develop new 
strategies for their preparation.
[18]
 Epoxides and 
halohydrins are considered as similar chemical 
functionalities but they can offer different features 
that can be exploited chemoselectively. To show this, 
5-azido-1-bromopentan-2-one (1c) was reduced with 
LBADH, affording enantiopure bromohydrin 2c or 
epoxide 3c in high conversions (Table 1, entries 6 
and 10). These reactions were performed at 100 mg-
scale obtaining similar results. It was envisaged that 
these derivatives could be reduced to the highly 
reactive (non isolated) amino compounds that would 
spontaneously cyclisise
[19]
 affording prolinol or 
piperidin-3-ol through SN2 reactions (Scheme 4). We 
firstly decided to optimise the reduction step using 
some reducing reagents such as NaBH4 and H2-Pd/C 
but in case of 3c the oxirane moiety was unstable. 
However, by means of the Staudinger reaction using 
PPh3 and H2O,
[20]
 the desired reduction was 
successfully accomplished. In case of the amino 
epoxide, it spontaneously evolved into prolinol with 
inversion of the configuration following a 5-Exo-Tet 
process, instead of piperidin-3-ol through an impeded 
6-Endo-Tet route according to Baldwin‟ rules 
(Scheme 4, left).
[21]
 On the other hand, bromohydrin 
2c afforded the piperidine derivative as the sole 
product through a favoured 6-Exo-Tet pathway 
(Scheme 4, right).
[21]
 Once optimised all individual 
steps, enantiopure (R)-prolinol and (S)-piperidin-3-ol 
were obtained as the corresponding N-Boc and N-
CBz derivatives, respectively, through this three-step 
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procedure. These transformations could be performed 
following a one-pot protocol, although better yields 
were achieved when the Staudinger reduction was 
performed after isolation of (S)-2c or (S)-3c. This 
procedure shows an elegant chemodivergent strategy 
that can be applied to the synthesis of different 
heterocyclic-bearing scaffolds with good yields and 
optical purities. 
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Scheme 4. Biocatalysed chemodivergent synthesis of 
enantiopure N-protected (R)-prolinol and (S)-piperidin-3-ol. 
In conclusion, we have developed an efficient one-
pot chemo- and stereodivergent enzymatic process 
applied to the preparation of both enantiopure 
terminal epoxides or -bromo alcohols starting from 
the corresponding α-bromoketones just tuning the 
reaction conditions. This is a nice example of the 
application of the medium engineering
[22]
 to an 
enzymatic process to perform transformations using 
mild reaction conditions to achieve the selective 
formation of several derivatives in high yields 
choosing the stereochemistry by employing the 
appropriate biocatalyst. Furthermore, applying this 
chemodivergent methodology very interesting 
compounds such as prolinol or piperidin-3-ol could 
readily be synthesised. Other heterocycles may be 
prepared by selecting the suitable precursor. A more 
comprehensive study of the presented system is 
currently under way in our laboratories. 
Experimental Section 
Synthesis of (S)-N-CBz-piperidin-3-ol (S)-7.
[23]
 100 mg 
of 1c were incubated in Tris.SO4 buffer 50 mM pH 7.5 (20 
mL) containing NADPH (1 mM) and MgBr2 (1 mM) in the 
presence of 2-propanol (5% v v
-1
) and n-hexane (5% v v
-1
) 
with LBADH (10 U) for 18 h at 30 ºC. The reaction was 
extracted with Et2O (3 x 5 mL) and the organic layers were 
dried and evaporated. The crude was dissolved in THF (4 
mL), and PPh3 (2 equiv.) and H2O (2 equiv.) were added. 
The reaction was stirred for 24 h at room temperature. 
Then, the solvent was evaporated and the crude was 
extracted with CH2Cl2/HCl 3N. The aqueous phase 
obtained (10 mL) was set to pH 8-9 with a satd. solution of 
Na2CO3 3N and then CH2Cl2 (5 mL) and CBz-Cl (1.2 
equiv.) were added and the biphasic system was stirred for 
12 h. The crude was extracted with CH2Cl2 and was 
subjected to flash chromatography over silica gel eluted 
with EtOAc/CH2Cl2 (from 1:1 to 2:1) affording 
enantiopure (S)-7 (40%). 
1
H-NMR (300 MHz, CDCl3): 
1.40-1.50 (m, 2H, H4), 1.65-1.80 (m, 2H, H5), 1.91 (br s, 
1H, HOH), 3.01-3.13 (m, 2H, H6) 3.49-3.74 (m, 3H, H2+H3), 
5.03 (s, 2H, Hb) and 7.24 (m, 5H, Har); 
13
C-NMR (75 MHz, 
CDCl3): 22.2 (CH2, C4), 32.2 (CH2, C5), 44.0 (CH2, C6), 
50.6 (CH2, C2), 65.8 (CH, C3), 67.9 (CH2, Cb), 127.7 (C, 
Ci), 127.9 (2 CH, Cm), 128.4 (2 CH, Co), 136.6 (CH, Cp) 
and 155.6 (C, C=O). 
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